Print

Key management and founders

 

 

Scientific Leadership

 

Prof. Pablo V. Escribá.
Scientific leader & main founder

Professor of Cell Biology at the UIB. Director of the Molecular and Cellular Biomedicine research group. Main promoter and founder of Lipopharma, pioneer in the discovery of membrane-lipid therapy (MLT) and inventor of several MLT-based drugs. He has held senior research stages in USA (New York, Kansas City and Charleston), Switzerland (Geneve) and Hungary (Szeged)

 

Prof. Xavier Busquets.
President of Lipopharma’s SAB & co-founder

Professor of Cell Biology at the University of the Balearic Islands (UIB, Mallorca). Co-director of the Molecular and Cellular Biomedicine research group. Co-founder of Lipopharma with a key role in the development of the membrane-lipid therapy (MLT). He has held senior research stages in the USA (Kansas City, New York), Switzerland (Geneve) and the UK (London)


Key management team

 

Vicenç Tur, MBA
Chief Executive Officer & co-founder

Mr. Tur holds a Degree in Business (UIB), in Economics (UAB) and an MBA (Stirling University, UK). Mr Tur accumulates a long and rich experience in managing R&D projects in innovative Companies and had previous experience in the financial sector. He has been advisor to the Regional Government for R&D and industrial innovation policies and has participated actively in the set-up of several technology-based companies. 12+ years experience in successfully setting-up, managing and consolidating innovative projects in the biopharmaceutical space.

 

Antonio J. González, BSc
Managing Director

Mr. González holds a Degree in Business Administration and is responsible for financial management, accounting and general administration since 2010. Before joining Lipopharma Mr Gonzalez accumulated more than 25 years of experience in top financial, accounting and general administration positions in medium and large companies in the logistics (Seur) and international commerce (Central Mimbrera) space, among others.

 

Antoine Perier, DEA
Clinical Development & Quality Assurance

Antoine has more than 25 years of experience in supporting bio-pharmaceutical companies in their general and clinical development to ensure financial and scientific optimization, and regulatory compliance. With a degree in Biology and a Master of Research (DEA) in Reproductive Biology – Endocrinology, he has held operational and executive responsibilities at Sanofi, AnalyticA, Cardinal Systems (clinical CRO where he served as CEO for 18 years) and Crane Solutions.

 

Catalina Ana Rossello, PhD
Head of Scientific Area: Clinical R&D projects
Dr. Rossello holds a degree in Biology (UIB), a degree in Biochemistry (UIB) and a PhD in in Molecular Biology (Autonomous University of Madrid). After a postdoctoral fellow research position at Lund University (Sweden) and a senior research position at the UIB (with an European FP7 Marie Curie grant), she joined Lipopharma as senior research scientist (with a Felip Bauçà contract from the local Government) first and then as head of the clinical R&D scientific area. She is liaison with all other scientific areas to ensure the flow of laboratory discoveries to clinical development.


Victoria Llado, PhD.
Head of Lipopharma’s research Laboratory

Dr. Llado holds a degree in Biology (UIB) and a degree in Biochemistry (UIB) and a PhD in in Molecular Biology (UIB). After postdoctoral fellow research positions at the Gastro-Intestinal Unit of MGH, Harvard Medical School (Boston, MA, USA) at the Sanford-Burnham Medical Research Institute (San Diego, CA, USA) and at the UIB (with a grant from the Asociación Española Contra el Cancer, AECC), she joined Lipopharma as head of the laboratory facilities in December 2018.


Paula Fernandez, PhD
Head of Oncology Research & Biomarker discovery

Dr. Fernandez has a degree in Biochemistry (University of Oviedo) and a PhD in Biochemistry and Molecular Biology (University of Oviedo). After a brief period in the Biomedicine Laboratory directed by Dr. Pablo V. Escriba and Dr. Xavier Busquets (UIB), she joined Lipopharma in November 2013, after obtaining a Torres Quevedo contract. Her research is developed mainly in the fields of proteomics and molecular biology. She is leading the basic and applied research aimed at further elucidating 2OHOA’s mechanism of action in oncology and at the identification and development of biomarkers to support the clinical development of 2OHOA. She is the principal investigator of several scientific projects, including CLINGLIO, a 6.15M€ H2020 R&D Grant to fund a PIIB trial with 2OHOA for the treatment of glioblastoma.


Manuel Torres, PhD
Head of CNS research

Dr. Torres has a degree in Pharmacy and a Master in Physiology and Neuroscience (University of Seville). He earned his PhD in biomedical sciences working in a research project in the field of Alzheimer’s pathophysiology. With 10-years expertise in this field (five years as a PhD student and five more years as a senior scientist) and research stages at Sanofi-Aventis Research Centre (Paris, France) and the Catholic University of Leuven/VIB Center for Human Genetics (Leuven, Belgium), he has published several scientific articles in the fields of pathophysiology and pharmacology of neurodegenerative disorders. He joined the scientific team of Lipopharma in 2013.


Neil Dey, PhD
Business Development & Director of LPharma Inc.

Dr. Dey has more than 20 years of cross-functional experience in licensing, international alliances, strategic marketing, technology & product development, asset acquisition, M&A, market assessment and clinical trial management. He has held senior executive positions in several biopharmaceutical companies including LMBRI LLC, Definies Ag, Impath Inc., Genmethrax Inc. or Ciba-Geigy (Novartis).

 

 

Richard J. Taylor, PhD (Consultant)
Medical and Regulatory affairs

Dr. Taylor has extensive multi-national pharmaceutical company experience. Formerly Head of International Clinical and Regulatory Affairs with Zeneca Pharmaceuticals (now AstraZeneca), Dr. Taylor has held management positions with Fisons Pharmaceuticals (now part of Aventis) and The Wellcome Research Laboratories (now part of Glaxo SmithKline). Since 2001 he is Managing Consultant & Projects Director at The Medical & Regulatory Partnership Ltd (TMRP), a drug development consultancy specializing in global regulatory professional services. Richard has a successful track record building clinical research, medical and regulatory affairs capability and has been actively involved in the preparation and update of key regulatory documents (IB, IMPD) and formal interactions with the UK Regulatory Agency (MHRA) on behalf of Lipopharma since early 2011.

 

 

© 2019 Lipopharma | legal notice Copyright 2011 Lipopharma - Team. All Rights Reserved.
Joomla 1.7 templates by hostgator coupon and learn how to make a website